Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 5/20 | 0.40 |
| ▸ | GABRD | O14764 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.40 |
| ▸ | GABRE | P78334 | 5/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 5/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 5/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 5/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629754 | 0.89 | NR4A2 (0.40) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6334224 | 0.88 | NR4A2 (0.39) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6030492 | 0.80 | NR4A2 (0.52) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12480177 | 0.76 | PBRM1 (0.44) | PARP1GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL6325276 | 0.75 | ALDH1A1 (0.43) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6029944 | 0.73 | NR4A2 (0.73) | NR4A2MAPTALOX5IGF1R | |
| SCHEMBL6327452 | 0.73 | CYP4F2 (0.48) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6029933 | 0.72 | NR4A2 (0.57) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL6334125 | 0.72 | NR4A2 (0.74) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL6029910 | 0.72 | MAPT (0.66) | NR4A2GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | NR4A2 2418/4885PARP1 579/4885GABRP 4538/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | NR4A2 2139/4885PARP1 516/4885GABRP 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.